Treatment of iron deficiency anemia: Practical considerations

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 6, 2015, Pages 452-460

  Taylor, Sophia ^a   Rampton, David ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anemia; Hypersensitivity reactions; Intravenous iron; Iron deficiency; Oral iron

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; IRON DEXTRAN; IRON ISOMALTOSE; IRON SACCHARATE; IRON SALT; TRANSFERRIN;

ABDOMINAL PAIN; ALLERGIC REACTION; ATHEROSCLEROSIS; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; FECES COLOR; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IRON ABSORPTION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; MEDICATION COMPLIANCE; NAUSEA; NOMENCLATURE; PATIENT COMPLIANCE; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; TURNOVER TIME; WORLD HEALTH ORGANIZATION; ADOLESCENT; ANEMIA, IRON-DEFICIENCY; CHILD; FEMALE; INFANT; MALE; PREGNANCY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, IRON-DEFICIENCY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; IRON; MALE; PREGNANCY; TREATMENT OUTCOME;

EID: 84936851693     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2888     Document Type: Review

References (50)

1. Shander A, Goodnough LT, Javidroozi M, et al. Iron deficiency anemia - bridging the knowledge and practice gap. Transfus Med Rev. 2014; 28: 156-166.
2. WHO, UNICEF, UNU. Iron deficiency anemia: Assessment, prevention, and control. A guide for programme managers. Geneva, World Health Organization, 2001. WHO/NHD/01.3. http://www.who.int/nutrition/publications/en/ida-assessment-prevention-control.pdf. Accessed March 2015.
3. Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anemia. Gut. 2011; 60: 1309-1316.
4. Frewin R, Henson A, Provan D. ABC of clinical haematology: iron deficiency anaemia. BMJ. 1997; 314: 360-363.
5. Reinisch W, Staun M, Bhandari S, et al. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J Crohns Colitis. 2013; 7: 429-440.
6. Nathavitharana RL, Murray JA, D'Sousa N, et al. Anemia is highly prevalent among unselected internal medicine inpatients and is associated with increased mortality, early readmission and more prolonged hospital stay: An observational retrospective cohort study. Intern Med J. 2012; 42: 683-691.
7. Waldvogel-Abramowski S, Waeber G, Gassner C, et al. Physiology of iron metabolism. Transfus Med Hemother. 2014; 41: 213-221.
8. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014; 35: 155-161.
9. Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis. J Crohns Colitis. 2012; 6: 267-275.
10. Agarwal, R. Nonhaematological benefits of iron. Am J Nephrol. 2007; 27: 565-571.
11. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006; 12: 123-130.
12. Mehmood T, Auerbach M, Earley CJ, et al. Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease). Sleep Med. 2014; 15: 1473-1476.
13. Cook JD. Diagnosis and management of iron deficiency anemia. Best Pract Res Clin Haematol. 2005; 18: 319-332.
14. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. European Medicines Agency 2013. EMA/579 491/2013:1-3. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/06/WC500144874.pdf. Accessed March 2015.
15. Rampton DS, Folkerson J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014; 99: 1671-1676.
16. Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006; 26: 445-454.
17. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - A randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005; 100: 2503-2509.
18. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005; 100: 55-62.
19. Tolkien Z, Stecher L, Mender AP, et al. Ferrous sulphate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS ONE. 2014; 10: E0 117 383. doi:10.1371/journal.pone.0117383.
20. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85: 650-654.
21. Cherlow GM, Winkelmayer WC. Commentary: on the relative safety of intravenous iron formulations. New answers, new questions. Am J Hematol. 2010; 85: 643-644.
22. Werner T, Wagner SJ, Martinez I, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut. 2011; 60: 325-333.
23. Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: A randomized controlled trial in Cote d'Ivoire. Am J Clin Nutr. 2010; 92: 1406-1415.
24. Radulescu S, Brookes MJ, Salgueiro P, et al. Luminal iron levels govern intestinal tumorigenesis after apc loss in vivo. Cell Reports. 2012; 2: 270-282.
25. Nairz M, Haschka D, Demetz E, et al. Iron at the interface of immunity and infection. Front Pharmacol. 2014; 5: 152.
26. Kletzmayr J, Sunder-Plassmann G, Horl WH, et al. High dose intravenous iron: A note of caution. Nephrol Dial Transplant. 2002; 17: 962-965.
27. Auerbach M, Ballard H. Clinical use of intravenous iron: Administration, efficacy and safety. Hematology Am Soc Hematol Educ Program. 2010; 1: 338-347.
28. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: A systematic review. Curr Med Res Opin. 2013; 29: 291-303.
29. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005; 118: 1142-1147.
30. Makrides M, Crowther CA, Gibson RA, et al. Efficacy and tolerability of low-dose iron supplements during pregnancy: A randomised controlled trial. Am J Clin Nutr. 2003; 78: 145-153.
31. Zlotkin S, Arthur P, Antwi KY, et al. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. Paediatrics. 2001; 108: 613-616.
32. Shaffer JL, Higham C, Turnberg LA. Hazards of slow-release preparations in patients with bowel strictures. Lancet. 1980; 2: 487.
33. Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: Results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015; 21: 579-588.
34. Pisani A, Riccio E, Sabbatini M, et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anemia in CKD patients: A randomized trial. Nephrol Dial Transplant. 2015; 30: 645-652.
35. Radia D, Momoh I, Dillon R, et al. Anemia management: development of a rapid-access anemia and intravenous iron service. Risk Manag Healthc Policy. 2013; 6: 13-22.
36. Ganzoni AM. Intravenous iron-dextran: Therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970; 100: 301-303.
37. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011; 141: 846-853.
38. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113: 832-836.
39. Szebeni J. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology. 2005; 216: 106-121.
40. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur J Nanoparticles. 2012; 1: 33-53.
41. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977; 1: 466-469.
42. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004; 114: 371-376.
43. Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996; 28: 529-534.
44. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anemia. Lancet. 2007; 369: 1502-1504.
45. Simons FE, Ardusso LR, Bilo MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011; 4: 13-37.
46. Resuscitation Council UK. Emergency treatment of anaphylactic reactions. Guidelines for healthcare providers. https://www.resus.org.uk/anaphylaxis/emergency-treatment-of-anaphylactic-reactions. Accessed March 2015.
47. Ring J, Grosber M, Mohrenschlager M, Brockow K. Anaphylaxis: Acute treatment and management. Chem Immunol Allergy. 2010; 95: 201-210.
48. Vogel WH. Infusion reactions, diagnosis assessment, management. Clin J Oncol Nurs. 2010; 14: E10-E21.
49. Goss JE, Chambers CE, Heupler FA Jr. Systemic anaphylactoid reactions to iodinated contrast media during cardiac catheterization procedures: guidelines for prevention, diagnosis, and treatment. Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn. 1995; 34: 99-104.
50. Gafter-Gvili A, Steensma DP, Auerbach M. Should the ASCO/ASH guidelines for the use of intravenous iron in cancer- And chemotherapy- induced anemia be updated? Journal of the National Comprehensive Cancer Network. 2014; 12: 657-664.